Mesoblast to Host Analyst Call on Financial Results for First Quarter Ended September 30, 2019
November 21 2019 - 4:29PM
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular
medicines for inflammatory diseases, will host an analyst call to
discuss the financial results for the quarter ended September 30,
2019. The webcast will begin at 4.30pm EST Monday, November 25,
2019; 8.30am AEDT Tuesday, November 26, 2019.
The live webcast can be accessed via
https://webcasting.boardroom.media/broadcast/5dcdf529dbec873524b6116b
To access the call only, dial 1 855 881 1339 (U.S.), 1800 870
643 or 1800 809 971 ( Australia) or +61 2 9007 3187 (outside of the
U.S. and Australia). The conference identification code is
10002927.
The archived webcast will be available on the Investor page of
www.mesoblast.com
About MesoblastMesoblast Limited (ASX: MSB;
Nasdaq: MESO) is a world leader in developing allogeneic
(off-the-shelf) cellular medicines. The Company has leveraged its
proprietary cell therapy technology platform to establish a broad
portfolio of commercial products and late-stage product candidates.
Two products have been commercialized in Japan and Europe by its
licensees, and it has established commercial partnerships in Europe
and China for certain Phase 3 assets. In the United States,
Mesoblast has initiated submission of a rolling Biologics License
Application to the FDA to seek approval of its product candidate
for acute graft versus host disease following a successful Phase 3
trial, and is completing Phase 3 trials for its advanced heart
failure and chronic low back pain product candidates. Mesoblast’s
proprietary manufacturing process yields industrial-scale, frozen,
off-the-shelf, cellular medicines based on its mesenchymal lineage
cell platform technology. These cell therapies, with defined
pharmaceutical release criteria, are planned to be readily
available to patients worldwide. Mesoblast has locations in
Melbourne, New York, Singapore and Texas and is listed on the
Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For
more information, please see www.mesoblast.com, LinkedIn: Mesoblast
Limited and Twitter: @Mesoblast
For further information, please contact:
Julie Meldrum |
Schond Greenway |
Corporate Communications |
Investor Relations |
Mesoblast |
Mesoblast |
T: +61 3 9639 6036 |
T: +1 212 880 2060 |
E:
julie.meldrum@mesoblast.com |
E:
schond.greenway@mesoblast.com |
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jul 2023 to Jul 2024